Dementia - Pipeline Review, H2 2019 - ResearchAndMarkets.com

The "Dementia - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Dementia (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 21, 14, 50, 20 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 9 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System).

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Acadia Pharmaceuticals Inc
• Actinogen Medical Ltd
• AcuraStem Inc
• Adamed Sp zoo
• ADEL Inc
• AgeneBio Inc
• Aibios Co Ltd
• Alector Inc
• Allergan Plc
• Alterity Therapeutics Ltd
• Anavex Life Sciences Corp
• Annovis Bio Inc
• Asceneuron SA
• Axon Neuroscience SE
• Axovant Gene Therapies Ltd
• Biogen Inc
• BioXcel Therapeutics Inc
• Boehringer Ingelheim International GmbH
• Bolder Biotechnology Inc
• Cennerv Pharma (S) Pte Ltd
• Cortice Biosciences Inc
• Daewoong Pharmaceutical Co Ltd
• Denali Therapeutics Inc
• EIP Pharma LLC
• Eisai Co Ltd
• Eli Lilly and Co
• Ensol Biosciences Inc
• Enterin Inc
• EVER Neuro Pharma GmbH
• Galimedix Therapeutics Ltd
• Gismo Therapeutics Inc
• Guangzhou Magpie Pharmaceutical Co Ltd
• GW Pharmaceuticals Plc
• HanAll Biopharma Co Ltd
• Hyundai Pharmaceutical Co Ltd
• Immungenetics AG
• ImStar Therapeutics Inc
• Inhibikase Therapeutics Inc
• IntraBio Ltd
• INVENT Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• iQure Pharma Inc
• IRLAB Therapeutics AB
• Johnson & Johnson
• Kogenix Therapeutics Inc
• LA Cell Inc
• Lachesis Biosciences Ltd
• Luye Pharma Group Ltd
• MediPost Co Ltd
• MGC Pharmaceuticals Ltd
• Neuraltus Pharmaceuticals Inc
• Neurimmune Holding AG
• Neurodyn Cognition Inc
• NeuroScientific Biopharmaceuticals Ltd
• NLS Pharma Group
• Novartis AG
• Oryzon Genomics SA
• Otsuka Holdings Co Ltd
• P2D Inc
• Pacific Northwest Biotechnology LLC
• Park Active Molecules
• Passage Bio Inc
• Plico Biotech Inc
• Prevail Therapeutics Inc
• ProMIS Neurosciences Inc
• Prothena Corp Plc
• Psy Therapeutics Inc
• Rodin Therapeutics Inc
• SanBio Inc
• Sinfonia Biotherapeutics Inc
• Stemedica Cell Technologies Inc
• Sun Pharma Advanced Research Company Ltd
• SyneuRx International Corp
• TauRx Therapeutics Ltd
• Theranexus SAS
• UniQure NV
• Voyager Therapeutics Inc
• WAVE Life Sciences Ltd
• WhanIn Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xk4rks

View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005158/en/